Fintech PR
EIFO and Novo Holdings lead €14M round in Power-to-Peroxide pioneer HPNow
COPENHAGEN, Denmark, Sept. 19, 2023 /PRNewswire/ — HPNow, the pioneer in electrification of the hydrogen peroxide industry, announced the successful closing of a €14M round.
The equity round is led by The Export and Investment Fund of Denmark (EIFO) together with Novo Holdings. Other investors in the round include MatiTech – a sustainable water treatment solution provider in Sub Sahara, and existing investors Evonik Venture Capital and AP Ventures.
HPNow’s breakthrough electrochemical technology enables the safe and sustainable generation of a powerful green oxidant directly on site, using only water and electricity as inputs. The output solution breaks down to pure water and oxygen following use. HPNow is bringing to market a greener alternative to the conventional fossil-fuel based centralized production, transportation and handling of bulk hydrogen peroxide, offsetting as much as three tons of CO2eq per ton of hydrogen peroxide generated on site, compared to standard production techniques.
With applications across agriculture, process water, and the food and beverage sectors, HPNow’s solutions provide not only a sustainable alternative but an economically viable one, with strong payback as compared to traditional chemical-based water treatment. The company’s solutions can further be utilized towards the breakdown of hazardous micro-pollutants in drinking water originating from pharmaceuticals, cosmetics, and O&G industries.
Proceeds from this round of financing will primarily be used towards the scaling up of HPNow’s marketing, sales, technical support and production capacity, in order to address growing market demand.
“Danish Power-to-X pioneers like HPNow are leading the way to a more sustainable future. From agriculture to industry, their technology, originally developed at the Technical University of Denmark, represents a multi-billion euro market opportunity for safe, sustainable and affordable water treatment,” said Investment Director at EIFO, Jonas Bjaaland.
“For EIFO it is important to ensure that green capex intensive pioneers like HPNow can scale up and make their technology available for the world market. We do that by closing the funding gap with equity for now but will also at a later stage be able to provide debt and export credit in corporation with commercial banks. With this group of investors HPNow can take big steps towards achieving not only the world market goal but also the UN Sustainable Development Goals,” he added.
“Water is a vital resource for our planet and the people that inhabit it. With our investment we are striving to benefit people and the planet, so this endeavour into sustainable water treatment is a logical step for us. HPNow’s hydrogen peroxide generation technology contributes to the responsible use of one of the most precious resources we have, and we are very pleased to join the company on this journey,” Marcus Remmers, Partner at Bioindustrial Investments, Novo Holdings, added.
“This new investment round, led by top-tier investors EIFO and Novo Holdings, represents a strong endorsement of our technology and market offerings, and will enable us to take a major leap forward in our company’s development. With the strong backing of new and existing partners, our company is ready to take sustainable on-site peroxide generation to the next level,” said Ziv Gottesfeld, CEO at HPNow.
About HPNow
HPNow addresses growing global challenges in clean water and sanitation through its range of on-site, autonomous, safe, and sustainable ultra-pure hydrogen peroxide generation solutions. HPNow was spun out of the Danish Technical University (DTU) in 2015, and is now headquartered in Copenhagen, with sales representation across Europe, the Americas and Asia. HPNow’s solutions address water treatment professionals’ needs in market segments ranging from agriculture to industrial and drinking water treatment. HPNow is a technology and market leader in on-site generation of hydrogen peroxide and is continuously striving to further advance its technology and products in order to meet growing market needs and rising global demand.
About EIFO
The Export and Investment Fund of Denmark (EIFO) is the national promotional bank and export credit agency of Denmark combined in one new financial institution. EIFO provides a single point of access for Danish companies as well as for their foreign and domestic business partners who need risk-tolerant government capital. EIFOs main objective is to support Danish companies which can green the globe.
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
As of year-end 2022, Novo Holdings had total assets of EUR 108 billion.
About MatiTech
MatiTech Solutions specializes in transforming water from diverse sources into usable assets for various applications. MatiTech prides itself on offering cutting-edge technologies and expertise in the field of water treatment. MatiTech stands by its commitment to provide sustainable water treatment solutions in Sub-Saharan Africa.
About Evonik Venture Capital
Evonik Venture Capital generates strategic value and growth opportunities through investing and partnering with innovative start-up companies. With a fund size of €400 million, Evonik Venture Capital has made about 50 investments since 2012, both direct and fund investments. The investment scope ranges from early stage to growth stage with an investment volume of up to €15 million per portfolio company. From its office in Germany, the USA and China, EVC invests in innovative technologies in the areas of Nutrition & Care, Smart Materials, Specialty Additives and Digitalization, as well as in technologies to support Evonik’s Sustainability Strategy.
About AP Ventures
AP Ventures is headquartered in London and manages venture capital funds with a global mandate to invest in pioneering new technologies and businesses which aim to solve global challenges such as renewable energy integration and resource scarcity. AP Ventures has been investing in the hydrogen industry since 2013 and is recognised as a leading venture capital fund across this value chain. AP Ventures manages USD 395m of assets on behalf of 12 LPs and has invested in more than 20 technology companies across the hydrogen value chain.
Stay in the loop by following HPNow on LinkedIn, Facebook, Twitter and Instagram.
View original content:https://www.prnewswire.co.uk/news-releases/eifo-and-novo-holdings-lead-14m-round-in-power-to-peroxide-pioneer-hpnow-301930970.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News5 days ago
Clayfin Technologies and Jana Small Finance Bank Honored with Prestigious IBSi Digital Banking Award 2024
-
Latest News4 days ago
Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade
-
Latest News7 days ago
Colombia to showcase sustainable investment opportunities at the Investment Roadshow in London
-
Latest News5 days ago
HANDSHAKE SPEAKEASY IN MEXICO CITY NAMED AS THE BEST BAR IN NORTH AMERICA AS RANKING OF NORTH AMERICA’S 50 BEST BARS IS REVEALED AT THIRD ANNUAL AWARDS CEREMONY
-
Latest News6 days ago
Nium Expands Regional Footprint in Asia; Signs Partnership MOU with Indonesian Payments Infrastructure Leader, Artajasa
-
Latest News5 days ago
BINGHATTI LAUNCHES ITS DEBUT PROJECT ADJACENT TO DUBAI HILLS
-
Latest News5 days ago
SDAX Unveils World’s First Securitised Gold Tokens for Digital Exchange Users
-
Latest News5 days ago
Allfunds has partnered with Google Cloud to leverage AI-powered innovation and optimize its infrastructure.